drugset / Trial / NCT05360628

Evaluation of PK and Safety of D-0120 and Allopurinol

NCT05360628

Phase 0 Completed 20 enrolled InventisBio Co., Ltd
RandomizedParallel-groupOpen-labelOther

Summary

Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects

Timeline

Start
2021-11-01
Primary completion
2022-02-10
Completion
2022-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopurinol Small molecule
Subject D-0120 Unknown

Indications

No indication recorded.